George Yancopoulos Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

George Yancopoulos is Bd. Co-Chair, President & CSO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 310,460 shares of REGN, which is worth approximately $215 Million. The most recent transaction as insider was on Dec 31, 2025, when has been sold 28,570 shares (Common Stock) at a price of $772.09 per share, resulting in proceeds of $22,058,611. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 310K

60.52% 3M change

60.52% 12M change

Total Value Held $215 Million

GEORGE YANCOPOULOS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 31 2025	SELL Payment of exercise price or tax liability	$22,058,611 $772.09 p/Share	28,570 Reduced 8.43%	310,460 Common Stock
Dec 31 2025	BUY Exercise of conversion of derivative security	-	28,570 Added 7.77%	339,030 Common Stock
Dec 09 2025	SELL Payment of exercise price or tax liability	$92,510,929 $701.51 p/Share	131,874 Reduced 29.81%	310,460 Common Stock
Dec 09 2025	BUY Exercise of conversion of derivative security	$81,580,691 $555.67 p/Share	146,815 Added 24.92%	442,334 Common Stock
May 16 2024	SELL Open market or private sale	$48,646,500 $972.93 p/Share	50,000 Reduced 5.98%	786,383 Common Stock
May 15 2024	SELL Open market or private sale	$48,872,500 $977.45 p/Share	50,000 Reduced 5.64%	836,383 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$117,894,341 $953.83 p/Share	123,601 Reduced 13.36%	801,608 Common Stock

Feb 15 2024	BUY Exercise of conversion of derivative security	$69,030,474 $399.66 p/Share	172,723 Added 15.73%	925,209 Common Stock
Dec 11 2023	SELL Payment of exercise price or tax liability	$10,838,959 $844.09 p/Share	12,841 Reduced 1.68%	752,486 Common Stock
Dec 11 2023	BUY Exercise of conversion of derivative security	-	25,155 Added 3.18%	765,327 Common Stock
Dec 22 2021	SELL Payment of exercise price or tax liability	$189,171,567 $610.04 p/Share	310,097 Reduced 23.32%	1,019,653 Common Stock
Dec 22 2021	BUY Exercise of conversion of derivative security	$99,412,776 $224.78 p/Share	442,267 Added 27.43%	1,169,835 Common Stock
Aug 16 2021	SELL Open market or private sale	$30,799,856 $625.67 p/Share	49,227 Reduced 5.26%	887,483 Common Stock
Aug 13 2021	SELL Open market or private sale	$483,125 $625.0 p/Share	773 Reduced 0.08%	936,710 Common Stock
Aug 05 2021	SELL Open market or private sale	$30,003,000 $600.06 p/Share	50,000 Reduced 5.06%	937,483 Common Stock
Dec 30 2020	SELL Payment of exercise price or tax liability	$104,773,432 $483.25 p/Share	216,810 Reduced 20.87%	822,207 Common Stock
Dec 30 2020	BUY Exercise of conversion of derivative security	$20,712,050 $52.03 p/Share	398,079 Added 30.47%	908,303 Common Stock
Mar 10 2020	SELL Open market or private sale	$55,806,609 $473.68 p/Share	117,815 Reduced 18.54%	517,799 Common Stock
Mar 09 2020	SELL Payment of exercise price or tax liability	$61,420,542 $476.42 p/Share	128,921 Reduced 16.86%	635,614 Common Stock
Mar 09 2020	BUY Exercise of conversion of derivative security	$7,557,523 $30.63 p/Share	246,736 Added 25.68%	713,990 Common Stock
Feb 24 2020	SELL Open market or private sale	$49,631,740 $420.17 p/Share	118,123 Reduced 18.58%	517,799 Common Stock

George Yancopoulos

Bd. Co-Chair, President & CSO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account